Theoretical Medicine and Bioethics

, Volume 29, Issue 6, pp 371–386 | Cite as

Consenting to uncertainty: challenges for informed consent to disease screening—a case study

Article
  • 110 Downloads

Abstract

This paper uses chronic beryllium disease as a case study to explore some of the challenges for decision-making and some of the problems for obtaining meaningful informed consent when the interpretation of screening results is complicated by their probabilistic nature and is clouded by empirical uncertainty. Although avoidance of further beryllium exposure might seem prudent for any individual whose test results suggest heightened disease risk, we will argue that such a clinical precautionary approach is likely to be a mistake. Instead, advice on the interpretation of screening results must focus not on risk per se, but on avoidable risk, and must be carefully tailored to the individual. These points are of importance for individual decision-making, for informed consent, and for occupational health.

Keywords

Informed consent Clinical uncertainty Environmental health Occupational health Occupational disease Disease screening Risk Risk control Beryllium disease Disease prevention BeLPT Beryllium lymphocyte proliferation test Beryllium sensitization Rational decision-making 

References

  1. 1.
    Poulin, Maurice, and Sylvie Ricard. 2004. Le test sanguin de prolifération lymphocytaire au béryllium (belpt). Québec: Institut National de Santé Publique du Québec.Google Scholar
  2. 2.
    Marchand-Adam, S., F. Guillon, M. Brauner, and D. Valeyre. 2005. Bérylliose pulmonaire chronique (2e partie). Revue des Maladies Respiratoires 22: 271–287.Google Scholar
  3. 3.
    Newman, Lee S., Margaret M. Mroz, Ronald Balkissoon, and Lisa A. Maier. 2005. Beryllium sensitization progresses to chronic beryllium disease: A longitudinal study of disease risk. American Journal of Respiratory and Critical Care Medicine 171: 54–60.CrossRefGoogle Scholar
  4. 4.
    Judd, Nancy L., William C. Griffith, Tim Takaro, and Elaine M. Faustman. 2003. A model for optimization of biomarker testing frequency to minimize disease and cost: Example of beryllium sensitization testing. Risk Analysis 23: 1211–1220.CrossRefGoogle Scholar
  5. 5.
    Borak, Jonathan, Steven H. Woolf, and Cheryl A. Fields. 2006. Use of beryllium lymphocyte proliferation testing for screening of asymptomatic individuals: An evidence-based assessment. Journal of Occupational and Environmental Medicine 48: 937–947.CrossRefGoogle Scholar
  6. 6.
    Kreiss, K., Lee S. Newman, Margaret M. Mroz, and P.A. Campbell. 1989. Screening blood test identifies subclinical beryllium disease. Journal of Occupational Medicine 31: 603–608.CrossRefGoogle Scholar
  7. 7.
    Agency for Toxic Substances and Disease Registry. 2006. Testing for beryllium sensitization a community service. http://www.atsdr.cdc.gov/sites/brushwellman/docs/Be_FINAL_REPORT_NOV15_2006.pdf. Accessed 13 December 2007.
  8. 8.
    U.S. Department of Energy, Office of Worker Health and Safety. 1999. Chronic beryllium disease prevention program final rule: Economic analysis. http://www.hss.energy.gov/HealthSafety/WSHP/be/archives/CBDPP_Final_Economic_Analysis4.pdf. Accessed 13 December 2007.
  9. 9.
    Wilson, J.M.G., and G. Junger. 1968. Principles and practice of screening for disease. Geneva: World Health Organization.Google Scholar
  10. 10.
    UK National Screening Committee. 2003. Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. http://www.library.nhs.uk/screening/ViewResource.aspx?resID=59772&tabID=288&catID=6777. Accessed 13 December 2007.
  11. 11.
    Rosenman, Kenneth, Vicki Hertzberg, Carol Rice, Mary Jo Reilly, Judith Aronchick, John E. Parker, Jackie Regovich, and Milton Rossman. 2005. Chronic beryllium disease and sensitization at a beryllium processing facility. Environmental Health Perspectives 113: 1366–1372.CrossRefGoogle Scholar
  12. 12.
    Viet, Susan Marie, Janet Torma-Krajewski, and John Rogers. 2000. Chronic beryllium disease and beryllium sensitization at rocky flats: A case-control study. American Industrial Hygiene Association Journal 61: 244–254.CrossRefGoogle Scholar
  13. 13.
    Chronic beryllium disease prevention program, subpart C: Specific program requirements—medical removal. Code of Federal Regulations Title 10, Pt. 850.35, 2007 ed.Google Scholar
  14. 14.
    Faden, Ruth, and Tom Beauchamp. 1986. A history and theory of informed consent. New York: Oxford University Press.Google Scholar
  15. 15.
    Manson, Neil C., and Onora O’Neill. 2007. Rethinking informed consent in bioethics. Cambridge, UK: Cambridge University Press.Google Scholar
  16. 16.
    Occupational health and safety standards, subpart Z: Toxic and hazardous substances—air contaminants. Code of Federal Regulations Title 29, Pt. 1910.1000, 2007 ed.Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  1. 1.Department of PhilosophyUniversity of DelawareNewarkUSA
  2. 2.CADDRE Education and Outreach ManagerUniversity of Pennsylvania School of NursingPhiladelphiaUSA

Personalised recommendations